Humalog


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

insulin lispro, rDNA origin

,

HumaLOG

(trade name)

insulin lispro protamine suspension/insulin lispro injection mixtures, rDNA origin

,

HumaLOG Mix 75/25

(trade name),

HumaLOG Mix 50/50

(trade name)

Classification

Therapeutic: antidiabetics
Pharmacologic: pancreatics
Pregnancy Category: B
See for more information concerning insulins

Indications

Control of hyperglycemia in patients with type 1 and type 2 diabetes mellitus.

Action

Lowers blood glucose by:
  • stimulating glucose uptake in skeletal muscle and fat,
  • inhibiting hepatic glucose production.
Other actions of insulin:
  • inhibition of lipolysis and proteolysis,
  • enhanced protein synthesis.
A rapid-acting insulin with more rapid onset and shorter duration than human regular insulin; should be used with an intermediate- or long-acting insulin.

Therapeutic effects

Control of hyperglycemia in diabetic patients.

Pharmacokinetics

Absorption: Very rapidly absorbed from subcutaneous administration sites (within a few minutes).
Distribution: Identical to endogenous insulin.
Metabolism and Excretion: Metabolized by liver, spleen, kidney, and muscle.
Half-life: Approximately 1 hr.

Time/action profile (hypoglycemic effect)

ROUTEONSETPEAKDURATION
Insulin lispro subcutwithin 15 min1–2 hr3–4 hr
75% insulin lispro protamine suspension/25% insulin lispro injection subcutwithin 15 min2.8 hr24 hr

Contraindications/Precautions

Contraindicated in: Hypoglycemia; Allergy or hypersensitivity to insulin lispro; Hypoglycemia.
Use Cautiously in: Stress or infection—may temporarily ↑ insulin requirements); Renal/hepatic impairment—may ↓ insulin requirements; Must be used with a longer-acting insulin in patients with type 1 diabetes; Concomitant use with pioglitazone or rosiglitazone (↑ risk of fluid retention and worsening HF) Obstetric: Pregnancy may temporarily ↑ insulin requirements; Pediatric: Children <3 yr (safety of lispro insulin not established) or <18 yr (safety of 75/25 mix not established).

Adverse Reactions/Side Effects

Endocrinologic

  • hypoglycemia (life-threatening)

Local

  • lipodystrophy
  • pruritus
  • erythema
  • swelling

Miscellaneous

  • allergic reactions including anaphylaxis (life-threatening)

Interactions

Drug-Drug interaction

Beta blockers, clonidine, and reserpine may mask some of the signs and symptoms of hypoglycemia.Corticosteroids, thyroid supplements, estrogens, isoniazid, niacin,phenothiazines,, and rifampin may ↑ insulin requirements.Alcohol, ACE inhibitors, MAO inhibitors, octreotide, oral hypoglycemic agents, and salicylates, may ↓ insulin requirements.Concurrent use with pioglitazone or rosiglitazone may ↑ risk of fluid retention and worsening HFGlucosamine may worsen blood glucose control.Fenugreek, chromium, and coenzyme Q-10 may produce additive hypoglycemic effects.

Route/Dosage

Dose depends on blood glucose, response, and many other factors
Subcutaneous (Adults and Children) Initial dose range– 0.2–0.6 units/kg/day. Usual maintenance range–0.5–1.2 units/kg/day. Adolescents during rapid growth—<1.5 units/kg/day.

Availability

Insulin lispro: 100 units/mL in 10-mL vials, 3 mL cartridges and 3 mL disposable delivery devices
Insulin lispro protamine suspension/insulin lispro injection mixture: 75% insulin lispro protamine suspension and 25% insulin lispro injection—Humalog Mix 75/25 100 units/mL in 10–mL vials and 3–mL disposable delivery devices, 50% insulin lispro protamine suspension and 50% insulin lispro injection—Humalog Mix 50/50 100 units/mL in 3–mL disposable delivery devices

Nursing implications

Nursing assessment

  • Assess for symptoms of hypoglycemia (anxiety; restlessness; tingling in hands, feet, lips, or tongue; chills; cold sweats; confusion; cool, pale skin; difficulty in concentration; drowsiness; nightmares or trouble sleeping; excessive hunger; headache; irritability; nausea; nervousness; tachycardia; tremor; weakness; unsteady gait)and hyperglycemia (confusion, drowsiness; flushed, dry skin; fruit-like breath odor; rapid, deep breathing, polyuria; loss of appetite; unusual thirst) periodically during therapy.
  • Monitor body weight periodically. Changes in weight may necessitate changes in insulin dose.
  • Lab Test Considerations:
    • Monitor blood glucose every 6 hr during therapy, more frequently in ketoacidosis and times of stress. A1C may be monitored every 3–6 mo to determine effectiveness.
  • Overdose is manifested by symptoms of hypoglycemia. Mild hypoglycemia may be treated by ingestion of oral glucose. Severe hypoglycemia is a life-threatening emergency; treatment consists of IV glucose, glucagon, or epinephrine.

Potential Nursing Diagnoses

Noncompliance (Patient/Family Teaching)

Implementation

  • high alert: Medication errors involving insulins have resulted in serious patient harm and death. Clarify all ambiguous orders and do not accept orders using the abbreviation “u” for units, which can be misread as a zero or the numeral 4 and has resulted in tenfold overdoses. Insulins are available in different types and strengths. Check type, dose, and expiration date with another licensed nurse. Do not interchange insulins without consulting physician or other health care professional.
  • Do not confuse Humalog with Humulin.
  • Due to the short duration of action, insulin lispro must be used with a longer acting insulin, insulin infusion pump or in combination with oral sulfonurea agents.
  • Use only insulin syringes to draw up dose. The unit markings on the insulin syringe must match the insulin’s units/mL. Special syringes for doses <50 units are available. Use only U-100 insulin syringes to draw up insulin lispro dose. Prior to withdrawing dose, rotate vial between palms to ensure uniform solution; do not shake.
    • When mixing insulins, draw insulin lispro into syringe first to avoid contamination of regular insulin vial.
    • Insulin should be stored in a cool place but does not need to be refrigerated.
  • Subcutaneous: Administer insulin lispro within 15 min before a meal. Rotate injection sites. Do not administer IV.
    • May be administered via disposable external insulin pump. Do not administer solution that appears thickened, cloudy, discolored or contains particles. Store cartridges for pump in refrigerator. Do not mix with other insulins or solutions when used with pump. Choose a new infusion site and insertion site at least every 3 days. Discard cartridges after 7 days, even if solution remains.
  • Syringe Compatibility: May be diluted with sterile diluent for Humalog, Humulin N, Humulin 50/50, Humulin 70/30, and NPH Ilentin to a concentration of 1:10 or 1:2.
  • Intravenous Administration
  • Continuous Infusion: Administer IV under medical supervision with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia. Concentration: 0.1 unit/mL to 1.0 unit/mL. Diluent: 0.9% NaCl. Solutions of insulin lispro and 0.9% NaCl can be stored for 48 hrs in refrigerator, then used at room temperature for another 48 hr.

Patient/Family Teaching

  • Instruct patient on proper technique for administration. Include type of insulin, equipment (syringe, cartridge pens, external pumps, alcohol swabs), storage, and place to discard syringes. Discuss the importance of not changing brands of insulin or syringes, selection and rotation of injection sites, and compliance with therapeutic regimen.
  • Demonstrate technique for mixing insulins by drawing up insulin lispro first and rolling intermediate-acting insulin vial between palms to mix, rather than shaking (may cause inaccurate dose).
  • Explain to patient that this medication controls hyperglycemia but does not cure diabetes. Therapy is long term.
  • Instruct patient in proper testing of serum glucose and ketones. These tests should be closely monitored during periods of stress or illness and health care professional notified of significant changes.
  • Emphasize the importance of compliance with nutritional guidelines and regular exercise as directed by health care professional.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications or alcohol.
  • Advise patient to notify health care professional of medication regimen prior to treatment or surgery.
  • Advise patient to notify health care professional if nausea, vomiting, or fever develops, if unable to eat regular diet, or if blood glucose levels are not controlled.
  • Instruct patient on signs and symptoms of hypoglycemia and hyperglycemia and what to do if they occur.
  • Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding or planning to breastfeed.
  • Patients with diabetes mellitus should carry a source of sugar (candy, glucose gel) and identification describing their disease and treatment regimen at all times.
  • Emphasize the importance of regular follow-up, especially during first few weeks of therapy.

Evaluation/Desired Outcomes

  • Control of blood glucose levels in diabetic patients without the appearance of hypoglycemic or hyperglycemic episodes.

Humalog

(hyo͞o′mə-lôg′, -lŏg′)
A trademark for the drug insulin lispro.

Humalog

A brand name for INSULIN LISPRO.
References in periodicals archive ?
Humalog should not be taken by someone with low blood sugar (hypoglycemia) or by someone who is allergic to insulin lispro or any of the ingredients in Humalog.
The potential for serious harm is high if a patient receives or is given the wrong preparation of Humalog[R], especially if the rapid acting plain Humalog[R] is given, instead of the rapid intermediate acting Humalog Mix[R] products.
addition to Humalog (except when using an external insulin pump).
FCF generation is expected to remain indicative of the current rating, with FCF margin greater than 10% until the potential patent lapses of Cymbalta and Humalog in 2013.
The most common side effect of Humalog is hypoglycemia (low blood sugar) that may be severe and cause unconsciousness, seizures and death.
Analysis and review of Humalog including historical sales data
Humalog 200 units/ml KwikPen is a pre-filled pen which, if approved, will deliver the same amount of insulin with half the volume per injection as the currently marketed Humalog (insulin lispro 100 units/ml) KwikPen.
Cymbalta, Cialis, Alimta, Forteo and Humalog was especially encouraging.
It will initially produce Humalog, a drug launched by the company in 1996 and used for the treatment of diabetes.
Patient share estimates further reveal that preferences for short-acting analogues vary between surveyed countries but that Novo Nordisk's Novolog/NovoRapid and Eli Lilly's Humalog are more frequently used than Sanofi's Apidra.
Humalog U-200 KwikPen marks the first FDA approval of a concentrated mealtime insulin analog.